News from targovax A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 23, 2021, 01:16 ET Continued survival benefit in Targovax's ONCOS-102 trial in mesothelioma at the 21-month follow-up

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces ...

Feb 18, 2021, 01:39 ET Reminder: Invitation to Targovax's Capital Markets Day 18 February 2021

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital ...

Feb 15, 2021, 01:15 ET Targovax receives Fast-Track designation for ONCOS-102

Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces ...

Feb 11, 2021, 01:42 ET Agenda for Targovax's Capital Markets Day 18 February 2021

Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will host a virtual Capital ...

Feb 10, 2021, 01:18 ET Targovax and Papyrus Therapeutics enter research collaboration to develop novel ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces ...

Jan 06, 2021, 01:15 ET Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces ...

Dec 15, 2020, 01:30 ET Targovax ASA: Save the date - Capital Markets Day 2021

Targovax ASA invites investors, analysts and media to a Capital Markets Day on Thursday 18 February 2021 Event: Targovax Capital Markets Day Date: 18 ...

Dec 02, 2020, 03:20 ET Targovax ASA: Invitation to online presentation at 10:00 CET 2 December

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, will today...

Dec 01, 2020, 23:30 ET Targovax announces impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces ...

Nov 24, 2020, 01:15 ET Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases...

Nov 09, 2020, 10:48 ET Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

Nov 05, 2020, 01:37 ET Targovax ASA: third quarter 2020 results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...

Oct 28, 2020, 02:51 ET Targovax announces formation of new Scientific Advisory Board

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

Oct 19, 2020, 01:15 ET Targovax announces accepted abstract at SITC

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

Oct 13, 2020, 01:24 ET Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announced ...

Oct 12, 2020, 01:51 ET Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors

Targovax ASA ("Targovax" or "the Company") (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat ...

Jun 04, 2020, 02:16 ET Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

May 14, 2020, 03:04 ET Targovax Announces That the ONCOS-102 and Durvalumab Abstract is Selected for a Poster Discussion Session at ASCO

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

May 06, 2020, 01:20 ET Targovax Announces That Abstract on Interim Phase I Clinical Data From the Phase I/II Peritoneal Trial is Accepted at ASCO

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...

May 04, 2020, 01:20 ET Targovax Releases Update for Mesothelioma Trial Combining ONCOS-102 and Chemotherapy

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today releases...

Apr 30, 2020, 01:14 ET Targovax ASA Appoints Dr Victor Levitsky as Chief Scientific Officer

Targovax ASA (OSE: TRVX) announces the appointment of Dr Victor Levitsky, MD, PhD as Chief Scientific Officer (CSO). He will play a leading role in...

Apr 22, 2020, 01:11 ET Targovax and Valo Therapeutics Enter Collaboration to Develop RAS Neoantigen Coating of ONCOS Viruses Using PeptiCRAd Technology

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid...

Apr 03, 2020, 01:21 ET Targovax ASA Announces Proposed New Chairman of the Board

Targovax ASA (OSE: TRVX) announces that its nomination committee has nominated Mr. Damian Marron for election as Chairman of the Board at the...

Mar 11, 2020, 02:09 ET Targovax ASA: Fourth Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...

Mar 03, 2020, 01:14 ET Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...